Brilinta (ticagrelor) is currently under patent protection, and a generic version is not yet available. The patents protecting Brilinta are set to expire at different times, with the earliest anticipated expiration for the primary composition of matter patent around 2024. [1]
When Does Brilinta's Patent Protection End?
The patent landscape for Brilinta is complex, with multiple patents covering various aspects of the drug, including its composition, manufacturing, and methods of use. The main patent for the active pharmaceutical ingredient, ticagrelor, is expected to expire around 2024. However, additional patents, including those for specific formulations or methods of treatment, may extend protection for longer periods, potentially into the late 2020s or early 2030s. [1]
What Happens After Brilinta Goes Generic?
Once the relevant patents expire and any remaining market exclusivities conclude, generic manufacturers will be able to produce and market their own versions of ticagrelor. This typically leads to a significant decrease in the price of the medication, making it more accessible to patients. The availability of generic drugs can also increase competition within the market. [2]
Can Other Companies Make Generic Brilinta Before Patents Expire?
Generic companies can challenge existing patents through various legal mechanisms, such as Paragraph IV certifications under the Hatch-Waxman Act. If a generic company successfully challenges a patent or finds it invalid, they may be able to launch their generic product before the original patent expiration date. These challenges often lead to complex and lengthy litigation between the brand-name manufacturer and the generic challenger. [3]
How Does Brilinta Compare to Other Antiplatelet Medications?
Brilinta is a P2Y12 inhibitor, a class of drugs used to prevent blood clots in patients with acute coronary syndrome or who have had a heart attack or stroke. It works by preventing platelets from aggregating. Other medications in this class include clopidogrel (Plavix) and prasugrel (Effient). Each of these drugs has a different efficacy and safety profile, and the choice of medication depends on individual patient factors and medical history. [4]
What Are the Risks Associated with Brilinta?
Common side effects of Brilinta include bleeding, shortness of breath, and bradycardia (slow heart rate). The risk of bleeding is a significant concern for patients taking antiplatelet medications. Patients should discuss any potential side effects or concerns with their healthcare provider. [5]
Where Can I Find Information on Drug Patent Expirations?
Resources like DrugPatentWatch.com provide detailed information on drug patent statuses, expiration dates, and related legal challenges. These platforms are valuable for tracking the lifecycle of pharmaceutical patents and understanding when generic alternatives might become available. [1]
---
Sources:
[1] DrugPatentWatch.com. (n.d.). Retrieved from https://www.drugpatentwatch.com/
[2] (n.d.). United States Food and Drug Administration. Retrieved from https://www.fda.gov/
[3] (n.d.). U.S. Food & Drug Administration. Retrieved from https://www.fda.gov/drugs/abbreviated-new-drug-applications-andanas/patent-and-exclusivity-information-andexclusivity
[4] (n.d.). National Heart, Lung, and Blood Institute. Retrieved from https://www.nhlbi.nih.gov/
[5] (n.d.). National Library of Medicine. Retrieved from https://medlineplus.gov/